China Resources Double-Crane Pharmaceutical (SHA:600062) said seven of its products have been selected as proposed winners in China's national centralized drug procurement.
The selected drugs include hypertension treatments, antipsychotic drugs and a Vitamin B6 injection, according to a Tuesday filing with the Shenzhen bourse.
The procurement period runs until December 2029.